What is the recommended treatment protocol for adult heroin withdrawal, including opioid‑agonist induction, dosing, and adjunctive symptomatic management?

Heroin Withdrawal Treatment Protocol

Buprenorphine is the first-line treatment for adult heroin withdrawal, with an initial dose of 4–8 mg sublingual when the Clinical Opiate Withdrawal Scale (COWS) score reaches ≥8, followed by maintenance at 16 mg daily for indefinite duration. 1, 2

Pre-Induction Assessment

• Confirm active withdrawal using COWS – only administer buprenorphine when the score is ≥8 (moderate to severe withdrawal) to avoid precipitating severe withdrawal due to buprenorphine's high receptor binding affinity and partial agonist properties. 1, 2

• Verify timing since last heroin use – wait a minimum of 12 hours after the last dose of heroin or other short-acting opioids before initiating buprenorphine. 1, 2

• Screen for contraindications – identify QT-prolonging medications (contraindicated with buprenorphine) and high-risk benzodiazepine co-prescribing (FDA black-box warning for respiratory depression and death). 1

• Review the state Prescription Drug Monitoring Program to detect other controlled substances before starting treatment. 1

Day 1 Induction Protocol

• Initial dose: Administer 4–8 mg sublingual buprenorphine based on withdrawal severity when COWS ≥8. 1, 2

• Reassess after 30–60 minutes – if withdrawal symptoms persist, provide additional 2–4 mg doses at 2-hour intervals. 1

• Target Day 1 total dose: 8 mg (range 4–8 mg), though some protocols use up to 16 mg on Day 1. 1, 2

Day 2 and Maintenance Dosing

• Day 2 dose: 16 mg sublingual buprenorphine, which becomes the standard maintenance dose for most patients. 1

• Standard maintenance: 16 mg sublingual daily occupies approximately 95% of mu-opioid receptors and creates a ceiling effect on respiratory depression. 1

• Dose range: 4–24 mg daily may be used; once-daily dosing is preferred over twice-daily to reduce respiratory risk when combined with other sedatives. 1, 3

• Duration of treatment: There is no maximum recommended duration—patients may require treatment indefinitely, as maintenance therapy is substantially more effective than tapering for preventing relapse. 1, 2, 3

Adjunctive Symptomatic Management

Regardless of whether buprenorphine is used, add symptom-specific medications:

• Nausea and vomiting: Antiemetics such as promethazine or ondansetron. 1, 2, 4

• Diarrhea: Loperamide 2–4 mg as needed. 1, 2, 4

• Anxiety and muscle cramps: Benzodiazepines (use cautiously due to respiratory depression risk when combined with buprenorphine). 1, 2

• Autonomic symptoms (sweating, tachycardia, hypertension): Clonidine 0.1–0.2 mg every 6–8 hours or lofexidine (preferred in outpatient settings due to lower hypotension risk). 1, 4, 5

Management of Precipitated Withdrawal

If buprenorphine precipitates withdrawal (rare when proper timing and COWS thresholds are followed):

• Primary treatment: Administer additional buprenorphine (not less) to re-establish adequate receptor occupancy. 1

• Adjunctive therapies: Clonidine for autonomic symptoms, antiemetics for nausea, benzodiazepines for anxiety, and loperamide for diarrhea. 1

Discharge Planning and Harm Reduction

• Prescribe buprenorphine/naloxone 16 mg sublingual daily for 3–7 days or until the first follow-up appointment (the X-waiver requirement was eliminated in 2023, allowing any DEA-licensed provider to prescribe). 1, 2

• Provide a take-home naloxone kit and overdose prevention education – patients become more sensitive to opioid effects after withdrawal, markedly increasing overdose risk if they resume heroin use. 1, 2

• Offer hepatitis C and HIV screening and consider reproductive health counseling as part of comprehensive care. 1, 2

Alternative: Alpha-2 Adrenergic Agonists (Second-Line)

When buprenorphine is contraindicated, unavailable, or declined by the patient:

• Clonidine or lofexidine can be used as primary agents for managing autonomic withdrawal symptoms (sweating, tachycardia, hypertension, anxiety). 4, 6

• Lofexidine is preferred in outpatient settings because it causes significantly less hypotension than clonidine while maintaining similar efficacy. 4, 5, 6

• Lofexidine dosing: Start with three 0.18 mg tablets orally four times daily (5–6 hours between doses) during the first 5–7 days of peak withdrawal, with a maximum daily dose of 2.88 mg (16 tablets). 5

• Clonidine dosing: 0.1–0.2 mg every 6–8 hours, titrated based on withdrawal symptoms and blood pressure monitoring. 1, 4

• Evidence of inferiority: Buprenorphine demonstrates clear superiority over alpha-2 agonists, with lower average withdrawal scores, significantly higher treatment completion rates, and a number needed to treat of 4 (for every 4 patients treated with buprenorphine instead of clonidine/lofexidine, 1 additional patient completes treatment). 1, 2, 4

Common Pitfalls to Avoid

• Initiating buprenorphine when COWS <8 precipitates severe withdrawal. 1, 2

• Prescribing discharge doses below 16 mg daily often results in persistent withdrawal symptoms and treatment failure. 1

• Using alpha-2 agonists as first-line therapy when buprenorphine is available represents suboptimal care. 4

• Discontinuing buprenorphine once started precipitates withdrawal and dramatically increases relapse risk to more dangerous opioids. 1, 2

• Discharging patients on alpha-2 agonists without a definitive addiction-treatment plan – these agents only address acute withdrawal, not long-term recovery. 4